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Abstract
Background: Gene expression connectivity mapping has gained much popularity recently with a number of
successful applications in biomedical research testifying its utility and promise. Previously methodological research in
connectivity mapping mainly focused on two of the key components in the framework, namely, the reference gene
expression profiles and the connectivity mapping algorithms. The other key component in this framework, the query
gene signature, has been left to users to construct without much consensus on how this should be done, albeit it has
been an issue most relevant to end users. As a key input to the connectivity mapping process, gene signature is
crucially important in returning biologically meaningful and relevant results. This paper intends to formulate a
standardized procedure for constructing high quality gene signatures from a user’s perspective.
Results: We describe a two-stage process for making quality gene signatures using gene expression data as initial
inputs. First, a differential gene expression analysis comparing two distinct biological states; only the genes that have
passed stringent statistical criteria are considered in the second stage of the process, which involves ranking genes
based on statistical as well as biological significance. We introduce a “gene signature progression” method as a
standard procedure in connectivity mapping. Starting from the highest ranked gene, we progressively determine the
minimum length of the gene signature that allows connections to the reference profiles (drugs) being established
with a preset target false discovery rate. We use a lung cancer dataset and a breast cancer dataset as two case studies
to demonstrate how this standardized procedure works, and we show that highly relevant and interesting biological
connections are returned. Of particular note is gefitinib, identified as among the candidate therapeutics in our lung
cancer case study. Our gene signature was based on gene expression data from Taiwan female non-smoker lung
cancer patients, while there is evidence from independent studies that gefitinib is highly effective in treating women,
non-smoker or former light smoker, advanced non-small cell lung cancer patients of Asian origin.
Conclusions: In summary, we introduced a gene signature progression method into connectivity mapping, which
enables a standardized procedure for constructing high quality gene signatures. This progression method is
particularly useful when the number of differentially expressed genes identified is large, and when there is a need to
prioritize them to be included in the query signature. The results from two case studies demonstrate that the
approach we have developed is capable of obtaining pertinent candidate drugs with high precision.
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Background
Over the past few years gene expression connectivity
mapping has gained much popularity among biomed-
ical researchers because of its promising applications
as demonstrated by an increasing number of studies in
different research areas: drug discovery [1–5], drug re-
positioning [6–8], predictive toxicology [9], and chemical
carcinogenicity assessment [10], to name a few. The Con-
nectivity Map (CMap) concept was first introduced by
Lamb et al. [11] with the idea of using gene expres-
sion profiles/signatures to represent different biological
states, and then to establish the connections among these
states based on their gene expression patterns. The estab-
lishment of a connection between two biological states
may have different implications. If the connection was
made because the key set of genes were similarly up- or
down-regulated in the two states, it may indicate that
the two states have the same activated biological pro-
cesses or pathways, such as the autophagy process and an
autophagy enhancing compound fasudil identified in [12],
and consequently such a connection would be very useful
for gaining insights into the underlying mechanism of one
state based on the knowledge of the other, and vice versa.
On the other hand if the connection wasmade because the
key set of genes were oppositely regulated, it may indicate
that the two states negate each other. If one is an unde-
sirable state such as a disease, and the other is a chemical
compound-induced state, the compound may be useful to
treat that particular disease [13], as in the case of appli-
cation to inflammatory bowel disease [14], and human
skeletal muscle atrophy [15]. From a user point of view,
one important question often asked is: what is the best
way of making a gene expression signature that can repre-
sent the biological state of interest accurately and be able
to return meaningful biological connections?
Within the gene expression connectivity mapping
framework, there are three key components: reference
gene expression profiles, query gene signatures, and
expression pattern matching algorithms. To date, much of
the methodological development has been focused on the
first and the third components above [16–20]. One impor-
tant aspect related to the development has been the efforts
to reduce the high number of possible confounding factors
and consequent batch effects within the heterogeneous
CMap datasets, eg., by utilising filtering and normalisa-
tion steps to improve the signal to noise ratio [19], or
by explicitly considering the variability in the transcrip-
tional response and capturing the “consensus” response to
a compound across multiple cell lines and dosages [20].
In this paper, we are mainly concerned with the construc-
tion of query gene signatures, which was previously left to
users without much guidance. For discussing the rationale
of the “gene signature progression” method to be intro-
duced, we first outline the differences between reference
profiles and gene signatures in the context of connectivity
mapping.
The idea of using some form of molecular profile to
characterize a biological state is not completely new. In
essence this idea was the basis of many clinical prac-
tices. For example, various biochemical tests measure the
molecular profile of a patient, which can then be used
to infer or learn about the biological state of the patient
(being with a particular disease or healthy). The main
assumption behind the connectivity mapping concept is
the generalization of molecular profile (bio-marker) mea-
surement. In this case the bio-marker molecules are the
messenger RNAs of genes in an organism. Because of the
sheer number of different mRNAs measured, they collec-
tively provide a much richer and complex description of
the biological state than a few marker molecules could
achieve. Theoretically if we have identified all the different
molecules and their abundance in a cell, we will have an
exact specification of the cell’s biological state. The main
assumption underlying the connectivity mapping concept
was that the specification of the mRNA profiles as mea-
sured by microarrays can provide an adequate description
of the biological state. With this premise, we discuss here
the roles played by reference profiles and gene signatures
in the connectivity mapping framework.
As described previously [11, 16], a reference gene
expression profile contains the full list of genes that were
measured by the microarrays, and specifies their abun-
dance in one condition relative to another. Because a
reference profile contains information about each gene,
it is intended to provide a comprehensive description
of the biological state it represents. A query gene sig-
nature, on the other hand, is a short list of genes that
capture the most important features of a biological state.
Its difference to a reference profile is that a gene signa-
ture is not meant to provide the full description of how
each gene has changed its expression, but rather to pro-
vide the most prominent features in that biological state.
Obviously any biological condition (state) will have many
features/aspects, but they are not of equal importance. For
establishing the connection between two biological states,
one needs to decide what features to include in the gene
signature. The aim of gene signature construction is to
compile a list of genes that collectively capture the most
prominent features of the biological state it is intended
to represent. Here in this paper we propose a two-stage
process to achieve that goal.
The initial input is assumed to be from microarray
gene expression data that have been properly processed
through some common steps, such as quality control,
background correction, normalization, scaling or trans-
formations, where appropriate. These pre-processing
steps are very important in microarray data analysis and
some recent research focused on these aspects, eg [21, 22],
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but they are not in the scope of the present work. Our
starting point is that we have obtained the gene expression
dataset, from which the expression levels of the genes can
be quantified in the available biological samples. Given
these data, we propose the following two-stage process for
the construction of gene expression signature in connec-
tivity mapping: (1) differential gene expression analysis to
provide an ordered list of significant genes. (2) gene signa-
ture progression analysis to systematically determine the
minimum length of the gene signatures able to return sig-
nificant connections to reference drugs with an acceptable
false discovery rate. Detailed description of the approach
is presented in the following “Methods” section.
Methods: a two-stage process
A schematic workflow of the two-stage process is depicted
in Fig. 1. The aim of the first stage, differential expres-
sion analysis, is to derive a ranked list of DEGs (Differ-
entially Expressed Genes) together with their regulation
status (direction of differential expression in the treatment
condition relative to the control), which can serve as
an input to the general connectivity mapping process.
The second stage, gene signature progression analysis,
involves creating multiple gene signatures consisting of an
increasing number of top ranked genes, and then querying
the sscMap iteratively with gene signatures of increasing
length until a number of significant drugs are returned
with a pre-set acceptable false discovery rate.
The sscMap connectivity mapping framework was
developed previously to introduce a more principled sta-
tistical test in connectivity mapping [16, 17]. It was
bundled with 6100 compound-induced reference gene
expression profiles as its core database. When a user-
supplied query gene signature is presented to it, sscMap
calculates a connection score between the query sig-
nature and each set of reference profiles in the core
database, then performs computationally intensive per-
mutation tests, to assess the statistical significance of
each observed connection score. A number of drugs with
Fig. 1 Flow chart of the two stage process. The output from stage 1 is a ranked list of significant genes with their regulation status (direction of
differential expression in the treatment condition relative to the control). This is used as input to stage 2, gene signature progression. Starting from
k = 1, the top k genes are fed to sscMap as a query signature to pull out significant drugs. This process is run iteratively with increasing k until a
pre-set target FDR is achieved for the returned significant drugs
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significant connection to the query signature are then
returned as the results of this process.
Differential gene expression analysis
In general, differential gene expression analysis involves
two or more biological conditions. For gene signature
construction in connectivity mapping, we are mainly con-
cerned with cases where they are two conditions. One of
them is a control condition which serves as a reference
point. The other condition is the state of our interest, for
example, a disease state or a state as a result of some form
of biological, chemical, or genomic perturbation experi-
ment. This is similar to the construction of reference gene
expression profiles, where a vehicle control condition and
a drug treated condition are required.
An important issue in the differential gene expression
analysis is the multiple testing correction that must be
considered when conducting a large number of statistical
tests at the same time. When tens of thousands of genes
are being tested in the same analysis, the conventional
statistical significance level of 0.05, which was developed
for single statistical test, is no longer adequate. Purely by
chance, 5 % of the genes tested will turn out to have a
p-value less than 0.05 even if there is no difference at all
between the two biological conditions being compared.
To safeguard the findings of differential gene expression
against too many false positives creeping in, the false
discovery rate (FDR) has become a commonly accepted
measure to control in situations where multiple hypoth-
esis testing is involved [23]. This measure allows users
to estimate the number of false positives given the total
number of positive results obtained. An equivalent way
of achieving this goal is to control the expected number
of false positives directly, and then calculate the empirical
false discovery rate. For example, to control the expected
number of false positives to be Efp, one can set the thresh-
old p-value as Efp/N , where N is the total number of
hypotheses being simultaneously tested, and in the case
of microarray differential gene expression analysis, N is
the total number of genes (probesets) measured by the
microarrays. In this paper we set Efp = 1 to apply a tight
control on the expected number of false positives in differ-
ential expression analysis. This is very important because
it ensures we can have the confidence in the differentially
expressed genes declared.
With differential expression analysis providing a list
of significant genes, here comes a key guiding princi-
ple of gene signature construction: only genes that are
differentially expressed with stringent statistical sig-
nificance should be passed on to the next stage. One
immediate question is: what if the number of significant
genes in the differential expression analysis is so small that
no significant connections could be established in the sub-
sequent connectivity mapping step. In such a situation,
the guiding principle above should still prevail. A more
frequently encountered situation nowadays is that the
microarray experiments included a large number samples
and the studies were adequately powered, and a long list of
genes have passed the significance criteria in the differen-
tial expression analysis. But should we include all of them
in the subsequent connectivity mapping step? Is it nec-
essarily the better if we include more genes in the query
signature? To address these issues, the second step “gene
signature progression” comes into play.
Gene signature progression
Given a long list of differentially expressed genes (DEGs)
obtained rigorously, how should we proceed to gene
expression connectivity mapping using these genes as
input? Before describing the detailed procedure of gene
signature progression, it is useful to outline the ratio-
nales and motivation behind the idea. The gene sig-
nature progression procedure was conceived based on
the following argument: although a long list of signif-
icant genes have been identified with high statistical
rigor, these genes are not equally important in char-
acterizing the biological state of interest, and hence
they should have different weights. We need a way
to quantify the importance and contribution of these
genes. Here we adopt similar guiding principles used in
the construction of reference gene expression profiles
for sscMap. Briefly, (1) up-regulated genes and down-
regulated genes should be treated on a equal-footing
basis. (2) genes that are differentially expressed to a
greater extent or those with greater significance should
have more weight and thus receive higher ranks. Note
that in Reference [16] genes were sorted by the abso-
lute value of their log expression ratio (drug-treated state
over vehicle control). In the present case of gene signa-
ture construction we have the option of using statistical
significance p value to sort and rank the genes. Here
we describe two ways of sorting the genes and ranking
them.
• M1: sorting the genes by their p values
The first natural solution to ranking the genes is to
sort them by their p values in ascending order, with
the smallest p value ranked the highest. The rationale
behind this method is that the smaller the p value,
the more significant the differential gene expression.
• M2: sorting the genes by their absolute log expression
ratios
The argument supporting this method is that all
these genes have passed the statistical significance
criteria in the differential expression analysis step,
and they are all genuine differentially expressed
genes. Now it is a matter of ranking them based on
their biological effects. In this case, the absolute value
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of log expression ratio is chosen as the closest proxy
to quantify their biological effect.
It should be noted that the criteria in M1 and M2 are
not independent of each other, but they are strongly cor-
related. In achieving a small p value in the differential gene
expression analysis, the magnitude of differential expres-
sion (the log ratio) must be reasonably large as compared
to its variance. Large log ratio or small variance alone
would not necessarily lead to statistical significance. One
could argue that Method M1 is already well balanced
because the p value already contains information on the
magnitude of differential expression and the consistency
of the gene’s behavior across replicates. In the two case
studies of this paper, we appliedM1 in sorting and ranking
the genes.
After the genes have received their absolute ranks using
one of the methods above, they are given signed ranks
which are just the absolute ranks multiplied by +1 or −1
depending on the direction of their differential expression,
in a similar way as in the construction of reference gene
expression profiles [16]. Once signed ranks have been
assigned to all genes in the DEG list, we use this gene list
as an input to subsequent connectivity mapping analysis,
assuming that the genes with the highest (absolute) ranks
(regardless of signs) represent themost important features
of the biological state.
In order to return the most relevant connections to
our biological state of interest, we devised a “gene signa-
ture progression” procedure to systematically determine
the minimal (optimal) length of the gene signature that
can accurately represent the biological state. The gene
signature progression method proceeds as follows:
• Forming a gene signature
Given a ranked list of genes, we make a gene signature
consisting of the top k ranked genes, denoted by sk ,
where k is an integer from 1 to n, and n is the total
number of genes in the initial DEG list passed on
from the differential gene expression analysis.
• Querying sscMap
We use the signature sk as an input to query the
sscMap, which returns the connection scores of sk to
all the reference profile sets (drugs) and their
corresponding p-values.
• Calculating the empirical FDR of the returned
connections
We set a threshold p-value to determine if any
returned connections are statistically significant. In
our analysis the threshold p-value is set as Nfp/Nsets,
where Nfp is the number of false connections we are
prepared to tolerate and expected to have in the
results, and Nsets is the total number of reference sets
we are querying. Under this setting if we observe Np
as the total number of significant connections, we use
Nfp/Np to estimate the empirical false discovery rate
(eFDR) [24]. In this way for each run of connectivity
mapping using a gene signature sk , we get an eFDR,
which is a function of the signature length k.
• Progressively looping over the gene signatures sk ’s
Starting from k = 1 with step increment until k = n,
to obtain the eFDR for each sk ; break out from the
loop when the first eFDR ≤ α is observed, where α is
a pre-set FDR threshold.
• Target FDR achieved
Take the break-out k from the previous step as the
optimal length of the gene signature.
It is possible that after looping over all the progression
signatures, none has returned an eFDR≤ α. In such cases,
the gene signature with the smallest eFDR could be taken
as the optimal one. This is not ideal in terms of the eFDR
achievable, but nevertheless the result is just a reflection
of the underlying biology. From a user’s point of view, one
has then to decide, given the achieved false discovery rate,
whether one wants to follow up the findings or not.
Results
A “simulated experiment”
First, we carried out a “simulated experiment” to see if
the gene signature progression approach indeed allows the
capture of the most prominent feature of the biological
state for which we know the truth. For this purpose, we
created a gene signature for histone deacetylase (HDAC)
inhibitor based on the internal reference profiles of CMap
database. Among the over 1300 drugs profiled in the camp
reference dataset, the following drugs are known to be
HDAC inhibitors (HDACi): vorinostat, trichostatin A, val-
proic acid, HC toxin, sodium phenylbutyrate, scriptaid,
and MS-275. The number of individual reference profiles
for these drugs are listed in Table 1. To obtain an ade-
quate sample size and also to avoid possible dominance
of results by the drugs with large number of replicates,
eg, trichostatin A and valproic acid, we used the following
four drugs: HC toxin, sodium phenylbutyrate, scriptaid,
Table 1 Known HDAC inhibitors in the CMap reference dataset
Compound Replicates
Vorinostat 12
Trichostatin A 182
Valproic acid 57
HC toxin 1
Sodium phenylbutyrate 7
Scriptaid 3
MS-275 2
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andMS-275, which have relatively small numbers of repli-
cates in the dataset, to create the HDAC inhibitor gene
signature. We combined their data to obtain a single list
of ranked significant genes that are associated with these
HDAC inhibitors (see Additional file 1 for the full list of
104 significant genes and their rank order). The genes
were then sorted by the absolute values of their sum rank
scores, and finally we obtained an ordered list of genes
with signed ranks. As this was the result of combing
four HDAC inhibitors specified above, this gene list was
expected to represent the biological state(s) as induced by
these HDAC inhibitors. Using this list of ranked genes as
input, we performed the gene signature progression anal-
ysis, k = 5 was determined to be the minimum length
of gene signature that returned a number of significant
drugs connection with an overall FDR no greater than 0.1.
The results of sscMap connectivitymapping analysis using
this minimum length gene signature are presented in
Table 2. As can been seen from this table, not only the four
input drugs, HC toxin, sodium phenylbutyrate, scriptaid,
and MS-275, were identified as significantly connected
to the gene signature (as they were expected to be), the
other major HDAC inhibitors, vorinostat, trichostatin A,
and valproic acid were also pulled out as significantly
connected to the HDACi signature. It should be empha-
sized that the reference data for these 3 drugs, were not
involved at all in creating the HDACi gene signature. So
these results are reassuring because the gene expression
connectivity mapping framework and the gene signature
progression approach has worked very well in this “simu-
lated experiment”. From this experiment, we see the added
value of the gene signature progression approach to con-
nectivity mapping. As designed, it helped to capture and
Table 2 The significant connections returned from sscMap using
the HDACi optimal gene signature (k = 5) obtained from the
“simulated experiment”
Compound Replicates cscore p value zscore SM PS
Sodium phenylbutyrate 7 0.684 5.0E-06 7.93 1 1
Trichostatin A 182 0.822 5.0E-06 6.18 1 1
Scriptaid 3 0.928 5.0E-06 5.39 1 1
Valproic acid 57 0.323 1.0E-05 5.31 1 1
Rifabutin 3 0.880 5.0E-06 5.21 1 1
Vorinostat 12 0.890 5.0E-06 5.19 1 1
MS-275 2 0.954 5.0E-06 4.30 1 1
Withaferin A 4 0.729 2.0E-05 3.97 1 1
HC toxin 1 0.928 5.0E-06 3.59 1 1
2-deoxy-D-glucose 1 0.902 1.0E-05 3.49 1 1
All 7 known HDAC inhibitors, including those not used in signature generation,
were pulled out. SM (significance mark) = 1 indicates that the connection p value is
less than the preset threshold Efp/Nsets = 1/1309 ≈ 7.6 × 10−4; PS (perturbation
stability) is also shown here
highlight themost important feature of the biological state
being studied. In this case, it was HDAC inhibition. With-
out the gene signature progression step, an arbitrarily
chosen signature length would be often used, for exam-
ple, k = 50 or k = 100. Using signatures of these
lengths to perform gene expression connectivity map-
ping, these HDAC inhibitors would still be returned as
significant connections, but they were returned together
with many other drugs (see Additional file 2 for the
results of sscMaping using the k = 50 HDACi signature).
Due to the co-existence of many other seemingly signifi-
cant drugs, the main biological theme (HDAC inhibition)
could potentially be weakened or evenmasked. Therefore,
this example demonstrates that the signature progression
approach does what it was designed for: to help users cap-
ture themost important biological themewith sharp focus
and high precision.
A case study with lung cancer
As an example application of the gene signature progres-
sionmethod introduced here, we analyzed a public dataset
from an independent study [25], where the tumor and
paired normal tissues from 60 non-smoker female lung
cancer patients were profiled using Affymetrix Human
Genome U133 Plus 2.0 (HG-U133_Plus_2) microarrays.
We downloaded the 120 raw Affeymetrix CEL files from
the Gene Expression Omnibus (GEO) dataset GSE19804.
For connectivity mapping analysis we wanted to compile
a gene signature describing the deviation of tumors from
normals, so that we could have an accurate representa-
tion of the cancerous state. Raw microarray data were
pre-processed using the AffymetrixMAS5 algorithmwith
the scaling parameter sc = 500 as implemented in the R
package affy [26]. We then worked on the log2 scale by
transforming MAS5 values to log2MAS5. As the refer-
ence profiles in the connectivity mapping database were
generated using Affymetrix HumanGenomeU133A (HG-
U133A) microarrays, the common probesets (22277 in
total) between the HG-U133_Plus_2 and the HG-U11A
arrays were extracted. A paired-sample t test was applied
to each of the common probesets to identify which is dif-
ferentially expressed between the lung cancer condition
and the normal condition. With a sample size of 120 the
study was well powered for identifying differential gene
expression. As a result, 6313 probesets had a p-value less
than the threshold discussed above Efp/N = 1/22277 ≈
4.5 × 10−5. This gave an estimated eFDR of 1/6313 ≈
1.6 × 10−4, so we were very confident that these differ-
entially expressed genes all reflected some aspects of the
real biology. But feeding all these genes as part of the gene
signature to connectivity mapping would be difficult as
the gene signature is too long and it would overwhelm the
connectivity mapping algorithm. It is also very difficult for
human comprehension to include such a large number of
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“features” if one wants to get a better grasp of the biol-
ogy under study. This example demonstrates the needs for
some form of filtering and selection procedure so that the
major theme(s) of the biology be captured and the big pic-
ture is not buried under many minor details. To this end
we set to filter out the probesets that were less prominent.
We took the following steps to shorten the list of selected
genes: (1) Only genes that met the statistical significance
criteria were passed on to the next step; those regarded
as statistically non-significant were not considered fur-
ther. In this case we set to tolerate an expected number
of false positives Efp = 1 as outlined above. (2) Following
the previous step, we required genes to have a minimum
mean expression level across the two conditions. Specif-
ically, genes with mean log2MAS5 values less than 6 in
both conditions were excluded from further analysis. This
minimum value 6 for log2Mas5, although somewhat arbi-
trary, was based on our extensive experience dealing with
microarray data. The rationale of this filtering was that for
genes with low expression levels in both conditions, we
were less confident about their differential expression sta-
tus, and also because of their low expression levels, their
biological significance was considered less important than
those with higher expression. (3) Following the previous
step, we required genes to have a minimum expression
difference between the two conditions. Specifically, genes
with an absolute expression difference less than 1 were
excluded from further analysis. As we work on log2 scale
data, an absolute difference of 1, is equivalent to a fold
change (ratio) of 2 in MAS5 expression values. So essen-
tially we required genes to have a minimum fold change of
2, either up or down.
After the three filtering steps described, we still had
1779 probesets to work with. These served as our input
DEG list to the gene signature progression analysis with
connectivity mapping. These 1779 probesets were sorted
in ascending order of their p-values, the ones on top
of the sorted list were regarded as most important. We
were interested in compounds with potential inhibitory
effects on the tumorous state, therefore we looked for
the connections with negative connection scores and used
a one-sided test to calculate the p-value associated with
the signature-to-drug connection. Briefly, for an observed
connection score between the query signature and a ref-
erence expression profile, we generated 105 random gene
signatures of the same length, and calculated the con-
nections scores between these random signatures and the
reference profile. Each random gene signature is just a list
of genes randomly sampled (without replacement) from
all genes profiled in the reference dataset, with their up- or
down- regulation status randomly set, as detailed in [16].
The proportion of random scores that were less than the
observed connection score gave an estimate of one-sided
(left-sided) p-value, which was then used to determine
whether the observed score was statistically significant
or not. In our connectivity mapping analysis, the query
gene signature was compared to each set of reference
profiles derived from the same compound; a connection
score between the query signature and each reference set
was calculated and the corresponding left-sided p-value
was estimated as described above. The results returned
from sscMap with a given query signature included the list
of compounds examined, their connection scores to this
query gene signature, and the associated p-values.
We followed the gene signature progression procedure
by generating progression signatures of increasing length
k consisting of the top k probesets from the sorted DEG
list obtained. Our target false discovery rate was set mod-
erately as 0.1. Figure 2 shows a few snapshots in the gene
signature progression process. Panel (C) of this figure, for
example, shows the results of sscMap using the gene sig-
nature s300 as the query input, consisting of the top 300
ranked genes from the differential expression analysis. As
can be seen in this case, 7 compounds were above the hor-
izontal line, the position corresponding to the threshold
p-value. As we expected 1 false connections among these
significant compounds, the empirical FDR was calculated
as 1/7 ≈ 0.14, which was higher than the pre-set FDR
target 0.1. Therefore we needed to progress the gene sig-
nature further after this k = 300 sscMap run. By following
the gene signature progression procedure, we found that
k = 322 was the minimum signature length that returned
significant connections with an eFDR ≤ 0.1. This list
of gene was taken as our optimal gene signature for the
lung cancer-vs-normal comparison (See Additional file 3
for the full list of these 322 genes and their ranks) and
was then fed to sscMap to identify compounds that could
inhibit the lung tumorous phenotype, ormore precisely, to
identify compounds with potential to push the tumorous
state closer to the normal state. Gene-signature perturba-
tionmethod was employed in the subsequent connectivity
mapping analysis. The details of the gene signature pertur-
bation process, its motivation and rationale can be found
in our previous work [27]. In Table 3 we show the results of
connectivity mapping using this k = 322 signature, with a
perturbation stability score obtained for each drug.
Breast cancer case study
As the second example of applying the gene signature pro-
gression method, we analyzed the GEO dataset GSE15852
from an independent study on human breast cancers from
Malaysian patients of different ethnicity (Malays, Chinese
and Indian) [28]. In total 43 pairs of tumor and nor-
mal tissues were profiled using Affymetrix HG-U133A
microarrays. Similar to the lung cancer case study, the
microarray experiment raw CEL files were downloaded
from GEO, and processed using the MAS5 algorithm to
obtain the gene expression values. Log2 transformation
Wen et al. BMC Bioinformatics  (2016) 17:211 Page 8 of 11
−4 −2 0 2 4 6
0
1
2
3
4
5
6
zscore
−
lo
g1
0(
pv
al
ue
)
−4 −2 0 2 4 6
0
1
2
3
4
5
6
zscore
−
lo
g1
0(
pv
al
ue
)
−4 −2 0 2 4 6
0
1
2
3
4
5
6
zscore
−
lo
g1
0(
pv
al
ue
)
−4 −2 0 2 4 6
0
1
2
3
4
5
6
zscore
−
lo
g1
0(
pv
al
ue
)
a b
c d
Fig. 2 Snapshots of the gene signature progression process in the lung cancer case study. Each panel shows results of sscMap with the top k ranked
genes as the query signature, with k = 150,200,300, and 322, respectively for (a)–(d). This figure exemplifies the intermediate results of individual
steps in the gene signature progression process. The blue horizontal line indicates the position corresponding to the threshold p-value. Any points
above this line are considered statistically significant. The number of compounds significantly connected to the query gene signature (solid red
circles) are 2,4,7, and 10 respectively for panels (a)–(d). k = 322 is the optimal signature length at which the preset FDR target≤ 0.1 was first achieved
was applied to the MAS5 expression values, and subse-
quent analyses were carried out using log2Mas5 values.
This dataset was based on the same microarray plat-
form as the reference profiles in sscMap, namely the
Affymetrix HG-U133A microarray platform with 22283
probestes. Paired sample t test was applied to each of
the 22283 probesets individually and a two-sided p-value
obtained for each probeset. The threshold p-value was set
as 1/22283 ≈ 4.5× 10−5, any probeset with a p-value less
than this threshold was considered as statistically signifi-
cant. For this case study, 1241 probesets met this criterion
and were passed on to subsequent filtering. After filter-
ing out probesets whose absolute differential expression
is lower than 1, and those with mean expression levels
lower than 6.0 in both conditions, finally 368 probesets
were left to form the query gene signature. The filtering
process described above ensured that the genes (probe-
sets) included in the query gene signature met the criteria
of both statistical significance and biological significance.
These 368 probesets were finally sorted by their p-values
in ascending order. The complete list of these probesets
and their corresponding gene symbols can be found in
Additional file 4.
Following the gene signature progression process we
identified that k = 232 was the minimum length for the
gene signature to return significant drug connections with
eFDR ≤ 0.1, hence this was taken as the optimal length
of gene signature in our connectivity mapping analysis.
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Table 3 The significant connections returned from sscMap using
the Lung cancer optimal gene signature obtained from the gene
signature progression process in the case study with GSE19804
dataset
Compound Replicates cscore p value zscore SM PS
Trichostatin A 182 –0.072 1.0E-05 –4.33 1 1.00
Rofecoxib 6 –0.047 6.0E-05 –4.29 1 1.00
Calmidazolium 2 –0.110 1.0E-05 –4.23 1 1.00
MS-275 2 –0.108 7.0E-05 –3.87 1 1.00
Rifabutin 3 –0.080 7.0E-05 –3.76 1 1.00
Exemestane 1 –0.113 2.8E-04 –3.50 1 1.00
STOCK1N-35696 2 –0.082 3.0E-04 –3.38 1 1.00
1,5-isoquinolinediol 1 –0.107 4.5E-04 –3.31 1 1.00
Pioglitazone 11 –0.030 3.4E-04 –3.33 1 0.99
Gefitinib 1 –0.105 5.8E-04 –3.23 1 0.93
SM (significance mark) = 1 indicates that the connection p value is less than the
preset threshold Efp/Nsets = 1/1309 ≈ 7.6 × 10−4; PS (perturbation stability) is also
shown here
Gene signature perturbation was then applied to this k =
232 gene signature, and the perturbation stabilities calcu-
lated for each connection obtained. In Table 4 we show
the results of sscMap using this k = 232 gene signature
and with gene signature perturbation procedure applied.
Table 5 summarizes the key figures of the two case studies
described in this paper.
Discussion
It is worth noting that there are a couple common drugs
from the two case studies presented here. These are: Tri-
chostatin A (TSA) and exemestane. Trichostatin A is pri-
marily an antifungal antibiotic and also a potent inhibitor
of histone deacetylase (HDAC) activity. Its antitumor
Table 4 The significant connections returned from sscMap using
the breast cancer optimal gene signature based on the case
study with dataset GSE15852, comparing 43 breast tumors with
their paired normal tissues
Compound Replicates cscore p value zscore SM PS
IC-86621 4 –0.079 5.0E-06 –4.84 1 1.00
Trichostatin A 182 –0.080 5.0E-06 –4.07 1 1.00
Semustine 4 –0.082 1.0E-04 –3.82 1 1.00
W-13 2 –0.091 8.0E-05 –3.77 1 1.00
Copper sulfate 4 –0.066 1.5E-04 –3.63 1 1.00
Exemestane 1 –0.136 2.8E-04 –3.58 1 1.00
Vorinostat 12 –0.087 1.9E-04 –3.47 1 1.00
Danazol 4 –0.053 2.5E-04 –3.43 1 1.00
Dexverapamil 1 –0.127 5.8E-04 –3.34 1 1.00
15-delta prostaglandin J2 15 –0.051 6.4E-04 –3.20 1 0.73
Table 5 Summary of the two datasets analyzed in the case
studies
Dataset GSE19804 GSE15852
Disease Lung cancer Breast cancer
Samples Size 120 86
Samples Details 60 tumors 43 tumors
60 normals 43 normals
Total Genes (Probesets) 22277 22283
Threshold P-value 1/22277 1/22283
Significant Genes 6316 1241
Expression filtered 6066 1229
Differential expression Filtered
(Fold Change > 2)
1779 368
Gene Signature Progression
optimal length
322 232
Potential drugs 10 10
activity against breast cancer in vitro and in vivo has
already been demonstrated [29]. Several studies showed
that TSA can induce apoptosis in human breast cancer
cells, for instance, via targeting the mitochondrial respira-
tory chain and increasing mitochondrial reactive oxygen
species [30], or through the involvement of 15-Lox-1 [31].
While the use of exemestane in breast cancer has been
long documented [32], there is evidence that this com-
pound also has antiproliferative effect in lung cancer cells
[33], and it was even suggested as a new treatment option
for mesothelioma patients [34].
Among the candidate compounds returned from the
lung cancer case study, rofecoxib was shown effective
inhibiting the growth of small tumors in xenograft models
of non-small cell lung cancer, suggesting its potential value
as adjuvant therapy after surgery [35]. Perhaps, the most
interesting result is that gefitinib is among the significant
drug candidates. It is interesting to note that our gene sig-
nature in the lung cancer case study was based on expres-
sion data from Taiwan female non-smoker lung cancer
patients, while gefitinib has been reported in an inde-
pendent study to be highly effective in treating women,
non-smoker or former light smoker, advanced non-small
cell lung cancer patients of Asian origin [36]. This result is
indeed “spot-on” in obtaining pertinent candidate drugs.
In the two case studies presented here, we have used p-
values to sort and rank the genes (Method M1). But this
is not the only way that genes can be sorted and ranked.
The other method (M2) could be employed as well. As
both ranking methods (M1) and (M2) described in the
“Methods” section have their merits, sometimes it can
be difficult to argue for one against another. The third
way of ranking the genes can be a weighted combination
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of (M1) and (M2). For example, we can rank the genes
using method (M1) and method (M2) separately, so that
each gene receives two ranks, Rp and Re, based on p value
(statistical) and on effect (biological), respectively. Then
a weighted average of the two ranks can be calculated by
R = wpRp + weRe, where wp + we = 1. The weighted
average ranks eventually determine the final ranking of
genes. Finally it is also possible to incorporate exter-
nal biological knowledge to adjust the ranking achieved
above. Researchers will have to draw upon their exper-
tise knowledge in the subject area and to make a decision
on whether a given genes’s rank should be boosted or
lowered.
Conclusions
In this paper we introduced a gene signature progres-
sion method into connectivity mapping, which enables a
standardized procedure for constructing high quality gene
signatures. The essence is to determine the minimum
length of the gene signature that allows significant con-
nections returned with a target false discovery rate. This
progression method is particularly useful when the num-
ber of differentially expressed genes identified is large, and
when there is a need to rank and prioritize them to be
included in the final query signature. On the other hand,
if the number of differentially expressed genes is small,
the two-stage process proposed in this paper stipulates
that only the DEGs, but not others, should be included
in the final gene signature. This means that, if in the
end, after including all the DEGs into the query signa-
ture, the false discovery rate of returned drugs is too high,
one should then be cautious in following up the returned
drugs, because too high a FDR would mean a low rate
of success in any experimental validation attempt. So it
is important that the statistical rigor set out in the pro-
posed two-stage process should be adhered to. The results
from the two case studies demonstrate that the approach
developed here is capable of obtaining pertinent candi-
date drugs with high precision. Future development in
this area is likely to involve incorporating existing biolog-
ical knowledge stored in various biological databases in
a systematic and automated way, to augment the current
approach based on expression data.
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